MDS as an Immunoresponsive Disease

If approved, zenocutuzumab would be the first targeted therapy for neuregulin 1 fusion-positive lung and pancreatic cancers.

Matthew Hadfield, DO, discusses his passion for early-stage clinical trials and the need for more research into immunotherapy toxicities during the third episode of Emerging Experts.

Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.

In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD, discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.

In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.

Nadofaragene firadenovec maintained its durable clinical activity at 5 years in patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer.